A Phase II Study of Reduced Intensity Sibling Allogeneic Transplantation for Relapsed, Chemosensitive, PET-positive Hodgkin Lymphoma
- To document the toxicity, feasibility, and survival after reduced-intensity
conditioning followed by allogeneic hematopoietic stem cell transplantation from a
matched sibling donor in patients with relapsed, chemosensitive Hodgkin lymphoma.
OUTLINE: This is a multicenter study.
- Reduced-intensity conditioning: Patients receive fludarabine phosphate IV on days -7 to
-3, melphalan IV over 30 minutes on day -2, and alemtuzumab IV on day -1.
- Transplantation: Patients undergo donor stem cell infusion on day 0.
- Graft-vs-host disease (GVHD) prophylaxis: Patients receive cyclosporine IV or orally on
days -1 to 60, followed by a taper until 3 months post-transplantation, in the absence
- Donor-lymphocyte infusion (DLI): DLI is used for the eradication of mixed chimerism and
for the management of residual or relapsed disease. If necessary, patients undergo DLI
every 3 months until the desired endpoint is achieved or GVHD develops.
After completion of study therapy, patients are followed up every 3 months for 3 years.
This study is peer reviewed and funded or endorsed by Cancer Research UK.
Masking: Open Label, Primary Purpose: Treatment
3-year progression-free survival
Karl Peggs, MD
University College London (UCL) Cancer Institute